Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Immunocore, Ltd.
CEO Allan Bradley tells Scrip that “we're at the very beginning of what I believe will be an explosion of TCR-based therapeutics” and his start-up hopes to take a leading position.
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
Amicus is launching its Pompe disease treatment Pombiliti/Opfolda in the UK after announcing on the same day that it had secured reimbursement and marketing approval for the combination treatment. Meanwhile, Immunocore says it disagrees with NICE's rejection of its advanced uveal melanoma drug, Kimmtrak.
The Swiss major’s Q1 earnings show significant growth for Vabysmo, which poses a threat to competitor anti-VEGF drugs from the likes of Novartis and Bayer, even as overall group sales decreased.
- Gene Therapy, Cell Therapy
Drug Discovery Technologies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.